Background Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of
eligible individuals. Blood signatures might act as a standalone screening tool, refine the …

Rationale: Diaphragm dysfunction is frequently observed in critically ill patients with difficult
weaning from mechanical ventilation. Objectives: To evaluate the effects of temporary …

Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to
immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient …

Original research: Baseline metabolic tumor volume as a strong predictive and prognostic
biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective …

Simple Summary Due to the increase of molecular biomarkers to be characterized to tailor
therapeutic strategies for non-squamous non-small cell lung carcinoma (NS-NSCLC), it is …

Alternative splicing (AS) tremendously increases the use of genetic information by
generating protein isoforms that differ in protein–protein interactions, catalytic activity and/or …

Rationale: The characterization of new theranostic biomarkers is crucial to improving the
clinical outcome of patients with advanced lung cancer. Here, we aimed at characterizing the …

Early-stage treatment improves prognosis of lung cancer and two large randomized
controlled trials have shown that early detection with low-dose computed tomography (LDCT) …

Introduction The detection of a ROS1 rearrangement in advanced and metastatic lung
adenocarcinoma (LUAD) led to a targeted treatment with tyrosine kinase inhibitors with favorable …

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction
of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer …